Innovus Joins Eli Lilly and Novartis in the Race to Develop

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
203
Innovus Joins Eli Lilly and Novartis in the Race to Develop Products for Oncology (Cachexia) -- SECFilings.com

REDONDO BEACH, CA--(Marketwired - Jun 13, 2017) - SECFilings.com, a leading financial news and information portal offering free real time public filing alerts, recently published an article discussing Innovus Pharmaceuticals' ( OTCQB : INNV ) recent entry into the oncology market with its version of over-the-counter supportive care products for cachexia.

Most investors interested in oncology are focused on biotech companies or large pharmaceutical companies undergoing clinical trials, but there are other fast-entry large segments of the market that often go unnoticed and underserved. For example, cancer centers may provide exposure to patient care while over-the-counter drugs and clinical nutrition products aim to provide a better quality of life and may help alleviate cancer side effects. These are large opportunities that don't involve the high cost, potential dilution, and uncertainty of clinical trials.

Broadening Its Focus

Innovus Pharma is primarily known for its men's and women's health and vitality product lines, but recently it has expanded into respiratory disease and cancer-related treatment. While these may seem like unrelated fields, the company's core focus has always been developing over-the-counter products that are based in science with robust clinical data supporting them for large markets. These products are then marketed through its highly effective Beyond Human® platform and its extensive online presence and customer following.

On June 6, the company announced that it acquired an exclusive license to two Generally Recognized as Safe (GRAS) compounds for the treatment of cachexia and muscle growth and repair. U.S. Patent Application No. 15/509,438 -- and all related foreign worldwide patent applications -- provide the company with the exclusive rights to use thymol and carvacrol for the induction of increased skeletal muscle endurance, lean muscle mass, and reduced adiposity.

"The oncology supportive care market is a very large unmet medical market with limited choices to both physicians and patients," said Innovus Pharma CEO Dr. Bassam Damaj. "Companies such as Abbott have been selling several hundred million dollars of its powder medical foods such as Juven® into this market for years and we believe that products we develop utilizing thymol and carvacrol could add additional needed benefits and be more competitive."

Significant Unmet Needs

Cachexia is a condition characterized by weight loss and muscle wasting that leads to progressive functional impairment and ultimately death in many cases. It's a multifactorial syndrome with many mechanisms involved and is associated with several chronic diseases including COPD, kidney disease, heart failure, and especially cancers. In fact, the rate of cachexia in cancer patients is estimated to be between 40% and 50%.

The standard of care for cachexia is nutritional support, steroids to help build muscle, and exercise to help maintain muscle function. Despite these being effectively palliative care options, Market Intel Reports estimates that the market for cachexia care is over $1 billion.

In a clinical review published in 2016 in The Journal of Oncology Practice , Drs. Bruggeman, Kamal, LeBlanc, Ma, Baracos, and Roeland state, "In conclusion, cancer cachexia has a remarkable impact on the experiences of patients with cancer. Despite decades of research, few interventions are available."

Recent recognition of cachexia as a distinct condition has led to an influx of investment and clinical trials in the space, but these trials have so far proven disappointing. In a December 2015 article in Nature , Jose Garcia states, "I'm a little bit worried that if we don't see a successful clinical trial in the next five years, the dollars from the pharmaceutical industry to develop a treatment will go somewhere else. In my view, that would be a missed opportunity." Garcia is a clinical researcher focused on wasting disorders at the Michael E. DeBakey Veterans Affairs Medical Center in Houston, Texas.

Innovus' newly licensed compounds could change things. Pre-clinical studies have shown that the compounds induce a more than 37% increase in exercise tolerance and a 15% to 50% increase in muscle mass of certain body muscles. In a clinical nutrition product form, these compounds could be offered to patients over-the-counter to address the critical condition and potentially help mitigate the effects of the disease or at least slow its progression.

Looking Ahead

Innovus Pharmaceuticals has already been widely successful in growing its existing over-the-counter products. During the first quarter, the company reported revenue of $2.2 million and appears to be tracking to $8.8 million for the year at a minimum (revenues totaled $4.8 million in 2016), though management points to historical quarterly revenue patterns as a sign to expect revenues in the $10 million to $15 million range. Management currently anticipates that it will reach profitability upon hitting a $10 million revenue run rate while it has already moved much closer to profitability on a cash flow basis -- all while continuing to grow revenue.

Please follow the link to read the full article: http://analysis.secfilings.com/articles/179-i...y-cachexia

About SECFilings.com

Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx .

Contact: Paul Archie 406 862 2242 parchie@secfilings.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 52

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
CCTV-4 Revisits China's Enduring Academy Tradition

Updated Category News Views 76

Stone courtyards, old books and hard questions are getting prime time on CCTV-4, which is a more interesting programming bet than it may first appear. Enduring Chinese Academies, a ten-episode cultural exploration series from China Media Group's Global Chinese Programming Center, is built around a simple theme: “One academy, one spirit.” It begins airing November 22...

Continue Reading
Tigo's Guidance Gap Draws Lawsuit and Investor Scrutiny

Updated Category News Views 69

A Revenue Promise Hit the Wall Solar investing can turn ugly in a hurry when a supposedly near-term catalyst gets shoved down the calendar. That is the central bruise behind the securities class action involving Tigo Energy, not some arcane accounting footnote that only lawyers can love. The complaint alleges Tigo overstated the revenue contribution it expected from its...

Continue Reading
Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 75

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
Trip.Best Expands Global Travel Discovery Footprint

Updated Category News Views 123

Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 73

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
PayPal Adds a Risk Hand to Its Board at a Crucial Turn

Updated Category News Views 48

A Boardroom Hire With Some Actual Weight PayPal did not go hunting for another decorative résumé. Brian J. Lee, set to join the board on November 30, 2026, spent decades inside Goldman Sachs, including a stint as chief risk officer from 2019 through January 2025. For a payments company trying to sharpen its financial-services identity, that is a serious piece of...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading
Milwaukee County Contract Tests Wisconsin Labor Shift

Updated Category News Views 6

A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 79

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading

Top 5 Most Recently Viewed Articles

Indovinya Unveils Challenge for Innovative Fragrance Solutions

Updated Category News Views 148

Indovinya Launches Open Innovation Challenge Researchers and startups with a focus on developing sustainable solutions for fragrance solubilization are invited to apply for an exciting new challenge initiated by Indovinya, the specialty chemicals and surfactants division of Indorama Ventures. The aim is to enhance fragrance solubilization without the use of ethoxylates,...

Continue Reading
Capricor Therapeutics to Highlight Innovations at Investor Events

Updated Category News Views 156

Capricor Therapeutics to Highlight Innovations at Investor Events Capricor Therapeutics (NASDAQ: CAPR), a leading biotechnology company based in San Diego, is committed to developing transformative cell and exosome-based therapies aimed at addressing rare diseases. Recently, the company announced a series of presentations scheduled at prominent investor conferences, where...

Continue Reading
Trump Media Takes Bold Step Into Financial Sector with New ETFs

Updated Category News Views 179

Trump Media's Financial Leap Trump Media & Technology Group Corp. (NASDAQ: DJT) is embarking on an exciting journey into the financial landscape. The company's fintech and streaming divisions are rolling out an innovative suite of five new exchange-traded funds (ETFs). These funds are crafted around the compelling themes of 'America First', aiming to appeal to socially...

Continue Reading
Vascular Access Device Market Set to Hit $8.68 Billion Milestone

Updated Category News Views 133

Overview of the Vascular Access Device Market The vascular access device market is on a promising trajectory, projected to escalate from around USD 6.27 billion to USD 8.68 billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.7%. This significant growth is positioned to enhance patient care in various healthcare settings, emphasizing the vital role of...

Continue Reading
Oscar Health: Navigating the Storm in Health Insurance Market

Updated Category News Views 269

Oscar Health: Understanding the Current Landscape The US health insurance sector is facing unprecedented challenges this year. With a significant number of individuals at risk of losing health insurance coverage due to substantial budget cuts, many are seeking medical care while they still can. This surge in demand has resulted in soaring utilization rates, pushing...

Continue Reading